Terms: = Breast cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4
63 results:
1. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative breast cancer.
Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
[TBL] [Abstract] [Full Text] [Related]
2. cdk12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract] [Full Text] [Related]
3. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
4. ERBB2-amplified lobular breast carcinoma exhibits concomitant cdk12 co-amplification associated with poor prognostic features.
Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
[TBL] [Abstract] [Full Text] [Related]
5. Genetic and clinical landscape of ER + /PR- breast cancer in China.
Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
[TBL] [Abstract] [Full Text] [Related]
6. Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and cdk12/13.
Ang HX; Sutiman N; Deng XL; Liu A; Cerda-Smith CG; Hutchinson HM; Kim H; Bartelt LC; Chen Q; Barrera A; Lin J; Sheng Z; McDowell IC; Reddy TE; Nicchitta CV; Wood KC
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2221448120. PubMed ID: 37695916
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7.
Jia M; Wang W; Chen G; Wu T; Zhang T; Zhou Q; Yin J; Li J; Li X; Mao Y; Feng J; Hu M; Li X; He F
Bioorg Med Chem Lett; 2023 Sep; 93():129429. PubMed ID: 37543274
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of a novel dual-target inhibitor of cdk12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
[TBL] [Abstract] [Full Text] [Related]
9. PhosphoDisco: A Toolkit for Co-regulated Phosphorylation Module Discovery in Phosphoproteomic Data.
Schraink T; Blumenberg L; Hussey G; George S; Miller B; Mathew N; González-Robles TJ; Sviderskiy V; Papagiannakopoulos T; Possemato R; Fenyö D; Ruggles KV
Mol Cell Proteomics; 2023 Aug; 22(8):100596. PubMed ID: 37394063
[TBL] [Abstract] [Full Text] [Related]
10. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
[TBL] [Abstract] [Full Text] [Related]
11. Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC; Militaru V; Crisan N; Bocsan IC; Udrea AA; Catana A; Kutasi E; Militaru MS
Biomol Biomed; 2023 Sep; 23(5):760-771. PubMed ID: 37021836
[TBL] [Abstract] [Full Text] [Related]
12. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract] [Full Text] [Related]
13. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of cdk12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Landscape of
Wang H; Miao J; Wen Y; Xia X; Chen Y; Huang M; Chen S; Zhao Z; Zhang Y; Chen C; Zhu X
Pathol Oncol Res; 2022; 28():1610360. PubMed ID: 35911441
[No Abstract] [Full Text] [Related]
16. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract] [Full Text] [Related]
17. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
18. cdk12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.
Filippone MG; Gaglio D; Bonfanti R; Tucci FA; Ceccacci E; Pennisi R; Bonanomi M; Jodice G; Tillhon M; Montani F; Bertalot G; Freddi S; Vecchi M; Taglialatela A; Romanenghi M; Romeo F; Bianco N; Munzone E; Sanguedolce F; Vago G; Viale G; Di Fiore PP; Minucci S; Alberghina L; Colleoni M; Veronesi P; Tosoni D; Pece S
Nat Commun; 2022 May; 13(1):2642. PubMed ID: 35550508
[TBL] [Abstract] [Full Text] [Related]
19. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract] [Full Text] [Related]
20. Noncovalent cdk12/13 dual inhibitors-based PROTACs degrade cdk12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract] [Full Text] [Related]
[Next]
